HOUSTON & NEW YORK--(BUSINESS WIRE)--
Bio-Path Holdings, Inc., (OTCQX: BPTH) (“Bio-Path”), a biotechnology
company developing a liposomal delivery technology for nucleic acid
cancer drugs, today announced that it has retained Maxim Group LLC, as a
financial advisor. Maxim will focus on assisting Bio-Path in its
strategies for maximizing shareholder value through its full scope of
investment banking services.
“We are excited to have such a successful and experienced investment
banking firm like Maxim Group to help guide the company into its next
phase,” said Peter Nielsen, President and Chief Executive Officer of
“We look forward to working with the Bio-Path team as it continues to
make progress with its proprietary liposomal delivery technology, which
has shown encouraging signals in blood cancer,” said Jim Alfaro,
Managing Director, Investment Banking for Maxim Group LLC.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking firm headquartered
in New York. Maxim provides a full array of financial services including
investment banking, equity research private wealth management, and
global institutional equity, fixed income and derivatives sales &
trading. The investment banking group focuses on middle market and
emerging growth companies within the healthcare, technology, energy,
shipping, retail, and business & financial services sectors. Maxim’s
institutional coverage spans North and South America, Europe and Asia.
Maxim Group LLC is registered as a broker-dealer with the U.S.
Securities and Exchange Commission and is a member of the following:
Financial Industry Regulatory Authority (FINRA), Municipal Securities
Rulemaking Board (MSRB), Securities Insurance Protection Corporation
(SIPC), NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about
Maxim Group, visit www.maximgrp.com.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic
products utilizing its proprietary liposomal delivery technology
designed to systemically distribute nucleic acid drugs throughout the
human body with a simple intravenous transfusion. Bio-Path’s lead
product candidate, Liposomal Grb-2, is in a Phase I study for blood
cancers and in preclinical studies for triple negative and inflammatory
breast cancers. Bio-Path’s second drug candidate, also a liposomal
antisense drug, is ready for the clinic where it is expected to be
evaluated in lymphoma and solid tumors.
Any statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties, including Bio-Path’s ability to raise needed additional
capital on a timely basis in order for it to continue its operations,
have success in the clinical development of its technologies, the timing
of enrollment and release of data in such clinical studies and the
accuracy of such data, limited patient populations of early stage
clinical studies and the possibility that results from later stage
clinical trials with much larger patient populations may not be
consistent with earlier stage clinical trials, and such other risks
which are identified in the Company's most recent Annual Report on Form
10-K and in any subsequent quarterly reports on Form 10-Q.These
documents are available on request from Bio-Path Holdings or at www.sec.gov.Bio-Pathdisclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Bio-Path Holdings, Inc.
Peter Nielsen, President & Chief Executive
Institutional Investors and
Rx Communications Group, LLC
Source: Bio-Path Holdings, Inc.